Nektar/BMS’s IL-2 Inhibitor Melanoma Failure Leaves Room For Other Contenders

 
• By Alaric DeArment
  
Cancer-cells-pink-color_1200x675
Nektar and BMS announced the failure of their Phase III melanoma study • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D